APO-GO

国: イスラエル

言語: 英語

ソース: Ministry of Health

有効成分:

APOMORPHINE HYDROCHLORIDE

から入手可能:

ABIC MARKETING LTD, ISRAEL

ATCコード:

N04BC07

医薬品形態:

SOLUTION FOR INJECTION / INFUSION

構図:

APOMORPHINE HYDROCHLORIDE 10 MG/ML

投与経路:

S.C

処方タイプ:

Required

製:

BRITANNIA PHARMACEUTICALS LTD, UK

治療群:

APOMORPHINE

治療領域:

APOMORPHINE

適応症:

Treatment of motor fluctuations (“on-off” phenomena) in patients with Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medication.

承認日:

2023-05-31

情報リーフレット

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/

製品の特徴

APO-GO-Ampoules-SPC-Notification-3-2021 - Clean
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
APO-go AMPOULES 10 mg/ml Solution for Injection or Infusion
_ * ABBREVIATED TO _APO-GO_ IN THE TEXT _
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains 10 mg apomorphine hydrochloride
2 ml contains 20 mg apomorphine hydrochloride
5 ml contains 50 mg apomorphine hydrochloride
Excipient(s) with known effect:
Sodium metabisulphite 1mg per ml
For the full list of excipients, see Section 6.1.
3.
PHARMACEUTICAL FORM
Solution for Injection or Infusion.
Clear, colourless or almost colourless, practically free from visible
particles.
pH 3.0-4.0.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
Treatment
of
motor
fluctuations
(“on-off”
phenomena)
in
patients
with
Parkinson's disease which are not sufficiently controlled by oral
anti-Parkinson
medication.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
_Selection of patients suitable for APO-go injections: _
Patients selected for treatment with APO-go should be able to
recognise the
onset of their ‘off’ symptoms and be capable of injecting
themselves or else
have a responsible carer able to inject for them when required.
Patients treated with apomorphine will usually need to start
domperidone at least two
days prior to initiation of therapy. The domperidone dose should be
titrated to the
lowest effective dose and discontinued as soon as possible.
Before the decision to initiate domperidone and apomorphine treatment,
risk
factors
for QT
interval prolongation
in
the
individual patient should be
carefully assessed to ensure that the benefit outweighs the risk (see
Section
4.4).
Refer to the domperidone prescribing information for recommended
domperidone
dosage information.
Apomorphine should be initiated in the controlled environment of a
specialist
clinic. The patient should be supervised by a physician experienced in
the
APO-GO-Ampoules-SPC-Notification-3-2021 - Clean
2
treatment
of
Parkinson’s
disease (e.g., neurologist). The patient’s tre